RSS-Feed abonnieren
DOI: 10.1055/s-0034-1372624
Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma
Publikationsverlauf
received 15. Dezember 2013
first decision 11. Februar 2014
accepted 25. März 2014
Publikationsdatum:
16. Mai 2014 (online)
![](https://www.thieme-connect.de/media/eced/201405/lookinside/thumbnails/10.1055-s-0034-1372624-1.jpg)
Abstract
Background: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of the BRAF V600E gene.
Aim: The aim was to 1) determine the association of lymph node metastases of PTC with the BRAF gene mutation of primary tumour; 2) evaluate association of the BRAF mutation in the primary tumour with clinicopathological parameters; 3) examine the extent of genetic heterogeneity by monitoring the BRAF mutation in multicentric tumours.
Subjects and methods: Retrospective analysis of the BRAF V600E mutation in PTC and PTC neck lymph node metastases in 156 patients operated from 2003 to 2012 in Prague and Zlín, the Czech Republic, using a qPCR assay. The results were correlated with clinicopathological factors.
Results: DNA was successfully extracted from 137 samples. The BRAF V600E mutation was detected in 78 cases (56.9%). The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR=2.39 (95%) CI 1.00–5.75, p=0.052]. In the classic papillary variant, the BRAF V600E mutation was found significantly more often than in other PTC subtypes (p=0.022). We did not confirm any significant association between the BRAF V600E mutation and other clinicopathological findings.
Conclusion: Except for the higher prevalence in papillary variant of PTC, BRAF p.Val600Glu mutation was not associated with other prognostic clinicopathological factors of PTC. BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC.
Key words
papillary carcinoma - BRAFV600E mutation - clinical and pathological parameters - neck node metastases* Both authors contributed equally to this work.
-
References
- 1 Hundahl SA, Fleming ID, Fremgen AM et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 1998; 83: 2638-2648
- 2 Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010; 22: 395-404
- 3 Becker HD, Hohenberger W, Junginger T et al. Chirurgicka onkologie 2005; 1: 1-880
- 4 Yeung MJ, Pasieka JL. Well-differentiated thyroid carcinomas: management of the central lymph node compartment and emerging biochemical markers. J Oncol 2011; 2011: 705305
- 5 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
- 6 Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res 2011; 17: 7511-7517
- 7 Gomez Saez JM. Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics 2011; 12: 597-608
- 8 Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-762
- 9 Bendlova B, Dvorakova S, Sykorova V et al. Nadory stitne zlazy – molekularne geneticke priciny a moznosti cilene lecby [Thyroid tumours – molecular genetics causes and targeted treatment possibilities]. Cas Lek Cesk 2012; 151: 123-127
- 10 Sykorova V, Dvorakova S, Ryska A et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 2010; 33: 318-324
- 11 Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369
- 12 Nucera C, Lawler J, Hodin R et al. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. Oncotarget 2010; 1: 751-756
- 13 Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid – A meta-analysis. Cancer 2007; 110: 38-46
- 14 Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J 2009; 56: 177-192
- 15 Liu RT, Chen YJ, Chou FF et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-466
- 16 Czarniecka A, Rusinek D, Stobiecka E et al. Occurrence of BRAF mutations in a Polish cohort of PTC patients – preliminary results. Endokrynol Pol 2010; 61: 462-466
- 17 Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
- 18 Kim TH, Park YJ, Lim JA et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-1773
- 19 Rivera M, Ricarte-Filho J, Tuttle RM et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid 2010; 20: 1085-1093
- 20 Xing M, Vasko V, Tallini G et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004; 89: 1365-1368
- 21 Zatelli MC, Trasforini G, Leoni S et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009; 161: 467-473
- 22 Abrosimov A, Saenko V, Rogounovitch T et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 2007; 120: 196-200
- 23 Durante C, Puxeddu E, Ferretti E et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843
- 24 Parisi F, Micsinai M, Strino F et al. Integrated analysis of tumor samples sheds light on tumor heterogeneity. Yale J Biol Med 2012; 85: 347-361
- 25 Fugazzola L, Puxeddu E, Avenia N et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006; 13: 455-464
- 26 Mani C, Selvakumar N, Kumar V et al. Comparison of DNA sequencing, PCR-SSCP and PhaB assays with indirect sensitivity testing for detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2003; 7: 652-659
- 27 Jiang W, Wang W, Fu F et al. A more sensitive platform for the detection of low-abundance BRAF(V600E) mutations. Mol Cell Biochem 2012; 366: 49-58
- 28 Kumagai A, Namba H, Akanov Z et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 2007; 54: 399-405
- 29 Namba H, Nakashima M, Hayashi T et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393-4397
- 30 Dusek L, Muzik J, Kubasek M et al. Epidemiology of Malignant Tumours in the Czech Republic. , Version 7.0 [online], Masaryk University, http://www.svod.cz [viewed September 13, 2013]. 2005
- 31 Curry JL, Torres-Cabala CA, Tetzlaff MT et al. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg 2012; 31: 267-273
- 32 Lin XQ, Finkelstein SD, Zhu B et al. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol 2008; 41: 195-203
- 33 Anderson S, Bloom KJ, Vallera DU et al. Multisite analytic performance studies of a real-time Polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012; 136: 1385-1391
- 34 Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010; 321: 86-93
- 35 Gouveia C, Can NT, Bostrom A et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013; [Epub ahead of print]
- 36 Guerra A, Sapio MR, Marotta V et al. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: 517-524
- 37 Eloy C, Santos J, Soares P et al. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 2011; 459: 265-276